

AD-HOC ANNOUNCEMENT

(pursuant to section 15 WpHG)

MeVis Medical Solutions AG
Universitaetsallee 29
28359 Bremen
Germany

Phone: +49 421 224 95 0
Fax: +49 421 22495 11
E-mail: ir@mevis.de

MeVis Medical Solutions AG: Outstanding purchase price payment reduced by € 1.6 million / Adjustment of forecast for the current fiscal year

Bremen, December 19, 2012 – MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, has managed to reduce the payment of the last tranche for the acquisition of the 49 % stake in MBS KG from originally € 3.0 million to € 1.4 million in a constructive dialogue with Siemens on the interpretation of a contract term. This payment is due at the end of 2012. Furthermore, a license credit to be granted by MeVis until 2015 is reduced by approximately € 0.4 million. This results in an overall reduction of liabilities by approximately € 2.0 million which will be booked against goodwill thus having no impact on earnings.

On that basis and on the basis of the current business development the forecast for the current fiscal year will be adjusted:

- For 2012 consolidated sales now will be expected to be slightly lower compared to the previous year.
- Through sustainable cost reductions both in personnel costs as well as other operating expenses a significantly increased consolidated EBIT of at least € 2 million is expected.
- Even considering the purchase price payment, a positive cash flow will be expected for 2012.

The Annual Report 2012 and the forecast for the next fiscal year will be published in April 2013.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.